On the stock market since 2001, it operates in the world of money and finance. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
An average decline of 18% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
The stock trades 32% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 121% a year on average.
Sales run at $24.3M a year. A small number, but proof the product has real buyers.
It pays out $0.70 per share each year — regular cash for whoever holds the stock.
A loss of $4.3M against $24.3M in annual sales.
At the current pace of spending, the cash lasts about 1.4 years. After that, the company needs to find new money.
On our five-subject report card, JRS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: JRS is a high-risk stock — not yet profitable, and its future rides on its product catching on.